Evidence map›Paper›PMID 29632712›Full record

ArticleOncoimmunology

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.

Paola Circosta, Angela Rita Elia, Indira Landra, Rodolfo Machiorlatti, Maria Todaro, Sabrina Aliberti, Davide Brusa, Silvia Deaglio, Sabina Chiaretti, Riccardo Bruna and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Review
  3. Humanized mouse models for immuno-oncology research.Nature reviews. Clinical oncology · 2023
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 4 countries.

Paola CircostaMolecular Biotechnology Center, University of Torino, Italy, and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
Angela Rita EliaMolecular Biotechnology Center, University of Torino, Italy, and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
Indira LandraDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
Rodolfo MachiorlattiDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
Maria TodaroDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
Sabrina AlibertiDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
Davide BrusaDepartment of Medical Sciences, University of Torino, Torino, Italy; Flow Cytometry and Cell Sorting Facility, Human Genetics Foundation, Torino, Italy.
Silvia DeaglioDepartment of Medical Sciences, University of Torino, Torino, Italy; Flow Cytometry and Cell Sorting Facility, Human Genetics Foundation, Torino, Italy.
Sabina ChiarettiDivision of Hematology, Department of Cellular Biotechnologies and Hematology, "Sapienza" University, Rome, Italy.
Riccardo BrunaUniversity Division of Hematology and Cell Therapy, University of Torino, Ospedale Mauriziano, Torino, Italy.
Daniela GottardiUniversity Division of Hematology and Cell Therapy, University of Torino, Ospedale Mauriziano, Torino, Italy.
Massimo MassaiaUniversity Division of Hematology and Cell Therapy, University of Torino, Ospedale Mauriziano, Torino, Italy.
Filomena Di GiacomoDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Anna Rita GuariniDivision of Hematology, Department of Cellular Biotechnologies and Hematology, "Sapienza" University, Rome, Italy.
Robin FoàDivision of Hematology, Department of Cellular Biotechnologies and Hematology, "Sapienza" University, Rome, Italy.
Peter W KyriakidesDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Rohan BarejaInstitute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medical College, 1300 York Avenue, New York, New York, USA[2] Institute for Precision Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, New York, USA.
Olivier ElementoInstitute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medical College, 1300 York Avenue, New York, New York, USA[2] Institute for Precision Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, New York, USA.
Gurunadh R ChichiliMacroGenics Inc., 9640 Medical Center Drive, Rockville, MD, USA.
Emanuele MonteleoneMolecular Biotechnology Center, University of Torino, Italy, and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
Paul A MooreMacroGenics Inc., 9704 Medical Center Drive, Rockville, MD, USA.
Syd JohnsonMacroGenics Inc., 9704 Medical Center Drive, Rockville, MD, USA.
Ezio BonviniMacroGenics Inc., 9704 Medical Center Drive, Rockville, MD, USA.
Alessandro CignettiMolecular Biotechnology Center, University of Torino, Italy, and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
Giorgio InghiramiDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
Cornell University · USUniversity of Turin · ITA. O. Ordine Mauriziano di Torino · ITMacroGenics (United States) · USSapienza University of Rome · ITItalian institute for Genomic Medicine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many patients with B-cell malignancies can be successfully treated, although tumor eradication is rarely achieved. T-cell-directed killing of tumor cells using engineered T-cells or bispecific antibodies is a promising approach for the treatment of hematologic malignancies. We investigated the efficacy of CD19xCD3 DART bispecific antibody in a broad panel of human primary B-cell malignancies. The CD19xCD3 DART identified 2 distinct subsets of patients, in which the neoplastic lymphocytes were eliminated with rapid or slow kinetics. Delayed responses were always overcome by a prolonged or repeated DART exposure. Both CD4 and CD8 effector cytotoxic cells were generated, and DART-mediated killing of CD4

Indexed as

B-cell malignanciesbispecific antibodiesCIK cellsDART CD19xCD3PDTX

Identifiers

PMID29632712
PMCPMC5889202
OpenAlexW2727279249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.